Biopsy-proven Histologic Scores clinical trials at UCLA
1 in progress, 0 open to eligible people
Showing trials for
ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Sorry, not yet accepting patients
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Los Angeles, California and other locations
Last updated: